Dr. Elisabeth Dimelis Henderson Ference, MD

Dr. Ference practices at Facey Medical Group - Valencia Specialty & Women's Center in Valencia, California.

Dr. Ference's NPI, 1457647067, was assigned on June 22, 2011. Dr. Ference graduated from Harvard Medical School in 2011. Dr. Ference holds California license A139909.

Dr. Ference's primary practice is Facey Medical Group - Valencia Specialty & Women's Center, at 23803 McBean Parkway, Valencia, CA 91355. The practice phone is (818) 869-7034.

Dr. Ference's primary practice is Facey Medical Group - Valencia Specialty & Women's Center in Valencia, California. Dr. Ference is also affiliated with Providence Holy Cross Medical Center. The medical group on file is USC Care Medical Group. Dmand AI also links Dr. Ference to 3 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ference practices, 5 sites in all. Vendor and product names are available with a free account.

Otolaryngology is Dr. Ference's primary specialty in the NPI Registry, under taxonomy code 207Y00000X. Dr. Ference is board certified in otolaryngology by the American Board of Otolaryngology - Head and Neck Surgery. Dmand AI has Dr. Ference's licenses on file in 2 states: California and Illinois.

Dmand AI lists acute sinusitis, chronic sinusitis, endoscopic sinus surgery, hearing loss and impairment, larynx and vocal cord disease, swimmer's ear, tinnitus and vertigo among the conditions Dr. Ference treats.

CMS data shows 275 Medicare services from Dr. Ference across 6 procedure codes in 2024, for 114 Medicare patients. Medicare paid $23,804 for them. Every service was in an office.

CMS counts 114 Medicare patients who saw Dr. Ference in 2024. The largest group is 65 to 74, with 63 patients. 73% of them have high cholesterol, and 68% have high blood pressure. 28% are also on Medicaid. Their average risk score is 1.18, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Ference's median patient age at 49, with 52% women.

In 2024, Dr. Ference wrote 332 Medicare Part D claims for 166 patients. 95% of them were for generic drugs. CMS names the drug for 237 of them, across 8 drugs with 11 or more claims each, at $3,656 in total drug cost. In 2023, CMS named 296 claims across 11 drugs.

Dr. Ference accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ference as offering telehealth.

Dmand AI links 22 papers to Dr. Ference, published from 2014 to 2023. 2020 was the busiest year, with 7. Dr. Ference has published most often in Otolaryngol Head Neck Surg. Dr. Ference's most frequent co-authors are Bozena Barbara Wrobel, MD, Rakesh Chandra, MD and David B. Conley, MD.

CMS Open Payments shows 130 general payments to Dr. Ference from 16 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 80% of the total. Sanofi and Genzyme US Companies paid the most, $57,452.

Dmand AI lists 6 awards for Dr. Ference, most recently Joshua Gordon Levitt Academic Excellence Award in 2021.

Dr. Ference graduated from Harvard Medical School in 2011. Dr. Ference is a member of NHS.

Dr. Ference is in network with 15 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.